Page 230 - Haematologica March 2020

A. Falgàs et al.
AB
C
D
EF
Figure 2. In vivo biodistribution and toxicity assessment of T22-GFP-H6 in the CXCR4+ subcutaneous (SC) Toledo mouse model. (A) Fluorescence intensity (FLI) detection in SC Toledo tumors at 2, 5 or 24 hours (h) after intravenous (IV) injection of 200 mg of T22-GFP-H6. No fluorescence was detected in buffer-treated mice. (B) Quantification of emitted fluorescence (measured as FLI ratio) at different times (2, 5 and 24h) in SC tumors and normal tissues (liver, spleen, heart, lungs, kid- neys and bone marrow). (C) FLI emitted by the nanocarrier in normal tissues 5h after T22-GFP-H6 administration. (D) Hematoxylin & Eosin (H&E) stained tissue sec- tions of normal organs and SC tumors at the 5h FLI peak. (E) Representation of the area under the curve (AUC) of emitted FLI over time (2-24h) registered in tumors, liver and lungs in T22-GFP-H6-treated mice. Notice that the AUC in the organs with an uptake lower than 2% (spleen, kidney, heart and BM) is not visible in this graph- ic. (F) Percentage of nanocarrier uptake (as measured by the AUC of emitted FLI) registered in each organ studied in relation to the total emitted FLI (sum of AUC in tumors and all studied normal organs) during the 2-24h period and expressed as mean±Standard Error of Mean (SEM). FLI ratio for experimental mice was calculated subtracting the FLI auto-fluorescence of control mice and dividing the FLI signal of each tumor/tissue by the FLI signal of the lungs (organ chosen as reference). Original magnification x400. BM: bone marrow.
744
haematologica | 2020; 105(3)